SCHEMBL11945195

SCHEMBL11945195

CCOC(=O)CCS(=O)(=O)N1CCN(c2cnn(-c3cc(F)cc(F)c3)c(=O)c2OC2CCCCC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.39
▸ NPY5R Q15761 2/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NCOA2 Q15596 1/20 0.34
▸ NCOA1 Q15788 1/20 0.34
▸ NCOA3 Q9Y6Q9 1/20 0.34
▸ NPBWR1 P48145 1/20 0.33
▸ MCHR1 Q99705 1/20 0.33
▸ TSHR P16473 2/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ DCTPP1 Q9H773 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.32
▸ GLA P06280 1/20 0.32
▸ ADORA1 P30542 1/20 0.32
▸ TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945175 0.86 MAPT (0.39) MAPTNPY5RNPSR1POLBCYP3A4
SCHEMBL11945602 0.85 MAPT (0.41) MAPTNPSR1POLBCYP3A4CYP2C19
SCHEMBL11944017 0.84 MAPT (0.41) MAPTNPSR1POLBCYP2C19NPBWR1
SCHEMBL11945147 0.84 MAPT (0.40) MAPTNPSR1POLBCYP3A4CYP2C19
SCHEMBL11946016 0.84 MAPT (0.39) MAPTNPY5RNPSR1POLBCYP3A4
SCHEMBL11945603 0.84 MAPT (0.40) MAPTNPY5RNPSR1POLBCYP3A4
SCHEMBL11945172 0.84 MAPT (0.42) MAPTNPSR1POLBCYP2C19NPBWR1
SCHEMBL11945471 0.83 NPBWR1 (0.39) MAPTNPY5RNPSR1POLBCYP3A4
SCHEMBL11944117 0.83 MAPT (0.46) MAPTNPY5RNPSR1POLBCYP3A4
SCHEMBL11944180 0.83 MAPT (0.43) MAPTNPSR1POLBCYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885NPY5R 4146/4885NPSR1 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback